YTTRIUM-90 ZEVALIN RADIOIMMUNOTHERAPY

PROCEDURE: After obtaining informed patent consent, Y-90 Zevalin therapy was administered intravenously for antibody therapy treatment of B-cell lymphoma.

DATE: 10/4/2005

DOSE: [30] mCi of Y-90 Zevalin

CLINICAL HISTORY: The patient is a [...]-year-old [fe]male with a history of [...]. Now referred for a Y-90 Zevalin radioimmunotherapy. 

CONCLUSIONS: 

The administration of Y-90 Zevalin was performed intravenously on an outpatient basis. The patient was given the usual precautions regarding radiation safety including avoiding close contact with pregnant women and young children for the next 48-72 hours. The patient states that there is no chance for her to be pregnant and has signed a statement, which was placed into the chart. The patient will be followed up by oncology.

Thank you for referring this patient to the UCLA Nuclear Medicine Clinic.

I, [...], M.D., Ph.D., have reviewed this Nuclear Medicine study personally, and am in full agreement with the findings of the report presented here.